암닐 파마슈티컬스(Amneal Pharmaceuticals, Inc.)
US ˙ NasdaqGS ˙ US03168L1052

SecurityAMRX / Amneal Pharmaceuticals, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership274,281 shares
Latest Disclosed Value $ 2,218,933
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 2.23% increase in ownership of AMRX / Amneal Pharmaceuticals, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 274,281 shares of Amneal Pharmaceuticals, Inc. (US:AMRX) valued at $2,218,933 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 268,307 shares of Amneal Pharmaceuticals, Inc.. This represents a change in shares of 2.23% during the quarter. The current value of the position is $3,771,364 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Amneal Pharmaceuticals EC US03168L1052 274,281 5,974 2.23 2,219 -1.33 0.0498
2025-05-28 2025-03-31 NP Amneal Pharmaceuticals EC US03168L1052 268,307 0 0.00 2,248 5.84 0.0539
2025-02-25 2024-12-31 NP Amneal Pharmaceuticals EC US03168L1052 268,307 -46,871 -14.87 2,125 -18.99 0.0464
2024-11-26 2024-09-30 NP Amneal Pharmaceuticals EC US03168L1052 315,178 87,504 38.43 2,622 81.45 0.0496
2024-08-26 2024-06-30 NP Amneal Pharmaceuticals EC US03168L1052 227,674 8,088 3.68 1,446 8.65 0.0294
2024-05-28 2024-03-31 NP Amneal Pharmaceuticals EC US03168L1052 219,586 0 0.00 1,331 -0.15 0.0278
2024-02-26 2023-12-31 NP Amneal Pharmaceuticals EC US03168L1052 219,586 9,263 4.40 1,333 50.17 0.0284
2023-11-28 2023-09-30 NP Amneal Pharmaceuticals EC US03168L1052 210,323 -459 -0.22 888 35.83 0.0232
2023-08-25 2023-06-30 NP Amneal Pharmaceuticals EC US03168L1052 210,782 52,554 33.21 653 198.17 0.0155
2023-05-26 2023-03-31 NP Amneal Pharmaceuticals EC US03168L1052 158,228 0 0.00 220 -30.25 0.0059
2023-02-24 2022-12-31 NP Amneal Pharmaceuticals EC US03168L1052 158,228 0 0.00 315 -1.57 0.0087
2022-11-25 2022-09-30 NP Amneal Pharmaceuticals EC US03168L1052 158,228 0 0.00 320 -36.58 0.0092
2022-08-25 2022-06-30 NP Amneal Pharmaceuticals EC US03168L1052 158,228 0 0.00 503 -23.67 0.0139
2022-05-26 2022-03-31 NP Amneal Pharmaceuticals EC US03168L1052 158,228 9,079 6.09 660 -7.70 0.0154
2022-02-25 2021-12-31 NP Amneal Pharmaceuticals EC US03168L1052 149,149 0 0.00 714 -10.30 0.0155
2021-11-24 2021-09-30 NP Amneal Pharmaceuticals EC US03168L1052 149,149 0 0.00 796 4.33 0.0175
2021-08-26 2021-06-30 NP Amneal Pharmaceuticals EC US03168L1052 149,149 0 0.00 764 -23.93 0.0164
2021-05-27 2021-03-31 NP Amneal Pharmaceuticals EC US03168L1052 149,149 4,861 3.37 1,004 52.20 0.0228
2021-02-25 2020-12-31 NP Amneal Pharmaceuticals EC US03168L1052 144,288 -25,508 -15.02 659 0.15 0.0169
2020-11-25 2020-09-30 NP Amneal Pharmaceuticals EC US03168L1052 169,796 0 0.00 659 -18.56 0.0211
2020-08-27 2020-06-30 NP Amneal Pharmaceuticals EC US03168L1052 169,796 -25,137 -12.90 808 19.17 0.0264
2020-06-01 2020-03-31 NP Amneal Pharmaceuticals EC US03168L1052 194,933 -8,726 -4.28 678 -30.89 0.0277
2020-02-27 2019-12-31 NP Amneal Pharmaceuticals EC 03168L105 203,659 61,646 43.41 982 138.69 0.0295
2019-11-27 2019-09-30 NP Amneal Pharmaceuticals EC US03168L1052 142,013 142,013 412 0.0136
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.